|
Senate BPCA, PREA Bill Bumps Up Deadlines, Grants FDA More Authority
Drugmakers would need to submit pediatric study plans to the FDA sooner in the drug development process under a bipartisan Senate bill that would make three programs intended to encourage pediatric trials of medical products permanent.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives